We’re just over a month away from the first Cancer Research Institute Immunotherapy Patient Summit and we’ve been blown away by the response to the event. The response has been so positive, we’ve had to increase capacity – twice!
As excitement builds, we wanted to share a sneak peek of the programming we’re planning for the Summit. Here’s what to expect:
As you can see, we’re bringing attendees experts in a wide range of topics – from oncologists, to advocates, to patients who’ve experienced immunotherapy firsthand.
We know this will be a valuable day to all to attend, and we’re proud to offer two ways to join in: either in person in New York City, or remotely, via our livestream. Either way, registration is free.
Click here to register to join us on the 24th, either in NYC or remotely.
The Cancer Research Institute Immunotherapy Patient Summit is made possible by generous support from Bristol-Myers Squibb, Merck, Genentech, and Regeneron.
- See more at: http://www.cancerresearch.org/news-publications/our-blog/august-2016/immunotherapy-patient-summit-agenda-announced#sthash.GsCyDCrl.dpuf
FDA Approves Pembrolizumab (Keytruda®), a PD-1 Antibody, for Head and Neck Cancer
Read Previous Article
CRI Congratulates 2016 Lasker Award Winners
Read Next Article
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
CRI hosted a Twitter Chat, moderated by STAT’s Sharon Begley, discussing takeaways from the ASCO19 conference last week.
ASCO19 highlighted a number of immunotherapy developments, including those relating to long-term survival, introducing immunotherapy earlier, biomarkers, and cellular immunotherapy.